#ALS Research #Switzerland #Zurich #NewCelX #Jeremy Shefner

NewcelX Enhances Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD

Introduction
In a significant step for its future innovations, NewcelX Ltd. has announced the appointment of Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board (SAB). Prof. Shefner, a prominent figure in the realm of neurology, brings extensive expertise to NewcelX, particularly in the study and treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). His affiliation as Chief Medical Officer at the Barrow Neurological Institute marks an essential addition to the company’s mission of developing impactful therapies.

Prof. Shefner's Background
A leading neurologist, Prof. Shefner has established a reputable career focusing on ALS and other neuromuscular disorders. His role at the Barrow Neurological Institute in Phoenix is notable; it is recognized internationally for its research and treatment of neurological conditions and boasts one of the largest multidisciplinary brain and spine programs in the United States. Moreover, it hosts the world's largest Phase 0 clinical trials program, paving the way for innovative neurotherapeutics.

Prof. Shefner has co-founded the Northeast ALS Clinical Trials Consortium (NEALS), uniting multiple centers to collaboratively address clinical trials concerning ALS. His academic contributions include over 200 peer-reviewed publications that discuss ALS biomarkers, clinical trial designs, and outcome measures—testaments to his dedication and impact in the field.

Strategic Role at NewcelX
On joining NewcelX's SAB, Prof. Shefner will play a pivotal role in providing strategic direction for the company's programs targeting ALS and facilitating clinical development of therapies such as AstroRx®. His unique expertise in neuromuscular and neurodegenerative diseases is expected to fortify NewcelX's broader platform that unites cell therapy with neuroscience innovations.

Ronen Twito, Executive Chairman and CEO of NewcelX, expressed his enthusiasm, stating, “We are very pleased to welcome Prof. Shefner to our Scientific Advisory Board. His leadership in ALS research and trial methodology strengthens our ability to bring advanced therapies to patients living with this devastating disease. His appointment underscores our commitment to scientific excellence and rigorous clinical execution.”

Prof. Shefner's Vision
Reflecting on his new role, Prof. Shefner mentioned, “It is a privilege to join NewcelX's SAB at this pivotal moment. I believe the Company's integrated approach—combining cell therapy and neuroscience—has significant potential to address ALS and other neurodegenerative diseases.”

About NewcelX Ltd.
NewcelX Ltd., listed on Nasdaq under the ticker NCEL, is a pioneering biotechnology firm developing novel cell-based and small molecule therapies for both neurodegenerative and metabolic diseases. The company skillfully merges advanced stem-cell technologies and neuroscience synergy to create scalable, transformative therapies aimed at conditions like ALS and Type 1 Diabetes. Headquartered in Zurich, Switzerland, NewcelX also executes research and development endeavors in Israel.

Conclusion
With Prof. Shefner's acclaimed expertise now part of its Scientific Advisory Board, NewcelX is poised to make significant strides in the therapeutic landscape of neurodegenerative diseases like ALS. The strategic guidance from such an esteemed figure not only enhances their scientific capabilities but also emphasizes the company’s dedication to addressing pressing health challenges through innovative solutions.

Stay tuned for developments from NewcelX as they embark on this exciting journey in medical biotechnology.